Clinical trials recruiting for Metastatic Prostate Cancer
45
Recruiting trials
33
US states with sites
15
Countries
2%
Accept healthy volunteers
Phase breakdown
Drugs and treatments being studied
Where trials are recruiting (top US states)
| State | Recruiting trials |
|---|---|
| Texas | 9 |
| Florida | 8 |
| California | 7 |
| New York | 7 |
| Maryland | 6 |
| Massachusetts | 6 |
| Michigan | 4 |
| New Jersey | 4 |
| North Carolina | 4 |
| Pennsylvania | 4 |
| Tennessee | 4 |
| Virginia | 4 |
Top cities
Houston, Texas 7Boston, Massachusetts 6New York, New York 6Baltimore, Maryland 4Nashville, Tennessee 4Durham, North Carolina 3Madison, Wisconsin 3Minneapolis, Minnesota 3Orlando, Florida 3Philadelphia, Pennsylvania 3
Self-screener
Recruiting trials
- 177Lu-PSMA-617 With Liver Directed Therapy in Metastatic Castration Resistant Prostate Cancer
- 18F-Fluciclovine PET/CT Impact on Predicting Clinical Outcome of 177Lu-PSMA-617 Therapy in Patients With Prostate Cancer
- 68Ga-PSMA PET/CT for Ra223 Assessment
- A Study Evaluating the Safety, Pharmacokinetics, and Activity of RO7656594 In Participants With Advanced or Metastatic Prostate Cancer
- A Study Evaluating the Safety, Pharmacokinetics, and Preliminary Activity of GDC-1261 in Participants With Advanced or Metastatic Prostate Cancer
- A Study of Evofosfamide in Combination with Zalifrelimab and Balstilimab
- A Study of Tarlatamab for People With Prostate Cancer
- ACTinium in Castrate-RESistant Prostate Cancer After LUTEtium
- Cabazitaxel +/- Carboplatin vs 177Lu-PSMA-617 in Metastatic Castrate-resistant Prostate Cancer
- Collection of Blood From Patients With Prostate Cancer
- Combination of TURP and Standard Systemic Therapy for MPCa
- Comparing the Efficacy and Safety of Rezvilutamide+ADT+Docetaxel Versus Rezvilutamide +ADT in the mHSPC
- Comparison of Different Methods of CAPTure of Circulating Tumour Cells (CTC) in Patients With Metastatic Breast or Prostate Cancer
- Creatine Supplementation and Resistance Training to Preserve Muscle Mass and Attenuate Cancer Progression
- Debunking the Frailty-sarcopenIa-ADT Axis in mEtastatic Prostate canceR With multiComponent Exercise: The FIERCE Trial
- Duration of Androgen Receptor Pathway Inhibitor and ADT With Metastasis Directed Therapy in Oligometastatic Cancer of the Prostate (DIRECT)
- Evaluating Dose Timing (Morning vs Evening) of Endocrine-based Therapies in Metastatic Breast and Prostate Cancers
- Feasibility and Impact of Liquid Biopsy Genomic Profiling on Treatment Patients With Metastatic Prostate Cancer in Spain (SOLTI-2102)
- First-in-Human Study to Evaluate AZD8359 STEAP2 TCE in Participants With Prostate Cancer
- First-in-human Diagnostic Imaging Profile of the Theranostic Pair [68Ga]Ga-DOTA-STR-17126 and Low Dose [177Lu] Lu-DOTA-STR-17126 in Patients With Advanced or Metastatic Cancer
- High Dose Testosterone for ATM, CDK12 or CHEK2 Altered Prostate Cancers
- Impact of Multimodal Telerehabilitation in Rural Patients With Metastatic Prostate Cancer
- Intermittent Darolutamide Treatment in the Triple Therapy of mHSPC
- Measuring Oncological Value of Exercise and Statin
- PRostate Cancer Plasma Integrative Multi-modal Evaluation
- PSMA PET-Guided Progression-Directed Radiotherapy for Oligoprogressive Prostate Cancer
- Pharmaceutical Management in Targeted Radioligand Therapy
- Phase 1 Trial to Study JANX013 and JANX007 Combination in mCRPC
- Phase Ib/II Platform Study of Multiple Anti-Cancer Agents in Participants With Metastatic Prostate Cancer
- Physician- and Patient-based Barriers to NGS Testing
- Pilot Study for Detection of PSMA-Low CRPC-NE Tumors With Fluciclovine PET/CT
- Platinum and Taxane Chemo in Met Castration Resistant Prostate Cancer Patients With Alterations in DNA Damage Response Genes
- Prostate Cryoablation Combined With Metronomic Cyclophosphamide for Metastatic Prostate Cancer
- Prostate Radiotherapy and Metastasis-Directed Therapy in Synchronous Oligometastatic Prostate Cancer
- Real-world Use of Lutetium (177Lu) Vipivotide Tetraxetan in China(PSMAreal CN)
- Remotely Monitored Exercise Interventions in Patients With mCSPC Undergoing ADT (Prostate 006)
- Study of AZD0516 as Monotherapy and in Combination in Participants With Metastatic Prostate Cancer
- Study of AZD0754 in Participants With Metastatic Prostate Cancer
- Study of HLD-0915 (JNJ-101556143) in Patients With Metastatic Prostate Cancer
- Study of ORIC-944 in Patients With Metastatic Prostate Cancer
- TOward a comPrehensive Supportive Care Intervention for Older Men With Metastatic Prostate Cancer
- Talazoparib Plus Enzalutamide After Progression to Abiraterone in Metastatic Prostate Cancer: (TEAM PC)
- The Impact of Radiotherapy on Oligometastatic Cancer
- Trial Targeting Gut Bacterial Androgen Production to Reverse Therapeutic Resistance to Abiraterone in Patients With Metastatic Prostate Cancer
- Veterans Affairs Seamless Phase II/III Randomized Trial of STAndard Systemic theRapy With or Without PET-directed Local Therapy for Oligometastatic pRosTate Cancer
Related conditions
Trials recruiting for Metastatic Prostate Cancer often also study these conditions. Each links to its own recruiting-trial list.
Prostate cancer 1234Metastatic breast cancer 131Breast cancer 2239Metastatic Castration-resistant Prostate Cancer 67Advanced Prostate Cancer 13Prostatic Neoplasms 36Urogenital Neoplasms 4Thyroid Cancer 21Recurrent Prostate Cancer 9Prostatic Neoplasms, Castration-Resistant 13
Common questions
Are these trials free to join?
Study-related care in a clinical trial is usually provided at no cost to participants, and some trials reimburse travel. Costs vary by study - the trial team will explain what is and is not covered. Confirm this directly with them.
How do I know if I am eligible for Metastatic Prostate Cancer trials?
Each trial lists inclusion and exclusion criteria. The screener above checks stated age and sex only. The full eligibility (your medical history, current medications, test results) is assessed by the study team. Open any trial to read its criteria, then contact the site.
Is this list complete?
No. For the full list, search ClinicalTrials.gov.